The FDA is proposing to remove semaglutide, tirzepatide, and liraglutide from the list of ingredients that outsourcing pharmacies can use to make bulk drug products. This change would prevent compounding pharmacies from manufacturing cheaper generic versions of these weight-loss and diabetes drugs.

• •FDA proposes excluding semaglutide, tirzepatide, liraglutide from 503B bulks list
• •Move would bar outsourcing facilities from compounding bulk versions of these drugs
• •Targets cheaper compounded alternatives to branded weight-loss and diabetes drugs

The FDA is proposing to remove semaglutide, tirzepatide, and liraglutide from the list of drugs that pharmacies can bulk-order for compounding (making custom doses). This would force patients to use brand-name versions of these weight-loss and diabetes drugs instead of cheaper pharmacy-made copies.

• •FDA proposes excluding semaglutide, tirzepatide, and liraglutide from 503B bulks list
• •Move would block pharmacies from bulk-ordering these APIs for compounding
• •Patients would be pushed toward brand-name versions

The FDA plans to remove semaglutide, tirzepatide, and liraglutide from the list of drugs that large-scale pharmacies can legally make in bulk (called 503B compounding). This change would force patients to buy these weight-loss and diabetes drugs from manufacturers instead of cheaper pharmacy-made versions.

• •FDA plans to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list
• •Move would block large-scale pharmacy bulk compounding of these GLP-1s
• •Patients would need to source from manufacturers rather than compounded versions

The FDA is proposing to remove semaglutide, tirzepatide, and liraglutide from the list of drugs that pharmacies can use to make bulk copies under 503B rules (a program that lets facilities make custom medicines). This change would prevent large-scale compounding of these weight-loss and diabetes drugs, likely pushing patients toward branded versions.

• •FDA proposes excluding semaglutide, tirzepatide, liraglutide from 503B bulks list
• •Change would block large-scale compounding of these GLP-1 drugs
• •Patients would be pushed toward branded versions

The FDA is proposing to stop pharmacies from making bulk copies of GLP-1 drugs (weight-loss and diabetes medications). This change could force more patients to buy expensive brand-name versions instead of cheaper compounded alternatives.

• •FDA proposing to end mass pharmacy compounding of GLP-1 drugs
• •Patients could be pushed toward brand-name versions
• •Compounded alternatives have been the cheaper option

The FDA is proposing new rules to limit pharmacies from making large quantities of generic copies of Novo Nordisk and Eli Lilly's weight-loss drugs. This could force patients to buy the more expensive brand-name versions instead of cheaper pharmacy-made alternatives.

• •FDA proposing rules to curb mass compounding of Novo and Lilly weight-loss drugs
• •Patients may be pushed toward more expensive brand-name versions
• •Targets pharmacy-made generic copies of GLP-1 weight-loss drugs

The FDA is proposing new rules to limit how much pharmacies can make generic copies of Novo Nordisk and Eli Lilly's weight-loss drugs. This could force more patients to buy the expensive brand-name versions instead of cheaper alternatives.

• •FDA proposing rules to limit pharmacy compounding of Novo and Lilly weight-loss drugs
• •Move could redirect patients to brand-name versions
• •Targets mass compounding of GLP-1 copies

The FDA is proposing to block pharmacies from making cheaper copies of GLP-1 weight-loss drugs, which would help Eli Lilly and Novo Nordisk sell more of their brand-name versions. This rule change could force patients to buy the expensive official medicines instead of lower-cost pharmacy-made alternatives.

• •FDA proposing to block pharmacies from compounding GLP-1 weight-loss drugs
• •Rule would favor branded versions from Eli Lilly and Novo Nordisk
• •Patients would lose access to lower-cost pharmacy-made alternatives

The FDA is taking steps to permanently ban pharmacies from making compounded versions of GLP-1 drugs (weight-loss and diabetes medications like semaglutide). This could force patients to buy more expensive brand-name versions instead of cheaper pharmacy-made copies.

• •FDA moving to permanently bar pharmacies from compounding GLP-1 drugs
• •Action targets compounded versions of semaglutide and related GLP-1s
• •Patients would be pushed toward more expensive brand-name products

The FDA is proposing to remove multiple GLP-1 drugs (a class of weight-loss and diabetes medicines) from a list of bulk ingredients that pharmacies are allowed to use to make cheaper compounded versions. This change could restrict pharmacies from making lower-cost copies and push patients toward buying more expensive brand-name versions.

• •FDA proposes excluding multiple GLP-1 RAs from the bulks list used for compounding
• •Move would restrict pharmacies from producing lower-cost compounded GLP-1 copies
• •Patients likely pushed toward higher-priced brand-name GLP-1 products

The FDA is proposing to remove weight-loss drugs from a list of medicines that pharmacies are allowed to make themselves (called compounding). This change could force patients to buy more expensive brand-name versions instead of cheaper pharmacy-made copies.

• •FDA proposing to exclude weight-loss drugs from pharmacy compounding list
• •Change would restrict pharmacies from making their own versions
• •Patients would face more expensive brand-name options

The FDA has signaled it will not add popular GLP-1 drugs (like semaglutide, a weight-loss medicine) to the 503B list, which allows certain pharmacies to make bulk copies of medicines. This decision means patients will likely need to rely on brand-name versions of these drugs rather than cheaper pharmacy-made alternatives.

• •FDA signals it will not add popular GLP-1 substances to the 503B bulks list
• •503B listing would have allowed outsourcing facilities to compound bulk GLP-1 copies
• •Patients likely steered back to brand-name GLP-1s over compounded alternatives

Novo Nordisk and Eli Lilly are proposing that their drugs be removed from a U.S. list that allows pharmacies to make cheaper copies. The change would make it harder for compounding pharmacies to create generic versions and could force more patients to buy the expensive brand-name drugs instead.

• •Novo Nordisk and Eli Lilly proposing removal of their drugs from a key US list
• •Change would restrict compounding pharmacies from making cheaper copies
• •Patients could be pushed toward brand-name versions

Novo Nordisk is making Ozempic tablets (semaglutide) available across the United States starting May 4. This is a pill version of the weight-loss and diabetes drug that was previously only available as an injection.

• •Novo Nordisk to make Ozempic tablets (semaglutide) available across the US starting May 4
• •Pill version of a drug previously available only as an injection

The FDA is stepping up enforcement actions against pharmacies that make cheaper copycat versions of GLP-1 weight-loss drugs like tirzepatide and semaglutide. The agency is tightening rules on which ingredients pharmacies can legally compound without brand-name drug company approval.

• •FDA stepping up enforcement against pharmacies compounding GLP-1 copycats
• •Action targets compounded tirzepatide and semaglutide
• •Agency tightening rules on ingredients pharmacies can compound without brand approval

A generic version of Novo Nordisk's GLP-1 drug has become available in Canada. Industry observers see this as an important test case for how generic GLP-1 drugs will compete with brand-name versions worldwide.

• •Generic of Novo Nordisk's GLP-1 drug has become available in Canada
• •Observers frame the launch as a test case for global generic GLP-1 competition

• •Novo Nordisk's oral Ozempic referenced as arriving to market

Novo Nordisk's oral version of Ozempic (semaglutide) is becoming available at pharmacies. The company is reporting earnings this week, and investors are watching closely to see how well the pill form performs.

• •Novo Nordisk's oral version of Ozempic (semaglutide) is reaching pharmacies
• •Novo Nordisk reports earnings this week
• •Investor focus is on early performance of the oral format

The FDA is considering restricting pharmacies' ability to make cheaper compounded copies of weight-loss drugs like semaglutide. This could force patients to buy the more expensive brand-name versions instead.

• •FDA weighing restrictions on pharmacy compounding of weight-loss drugs
• •Semaglutide named as a targeted compounded product
• •Patients could be pushed to higher-priced brand-name versions

• •Novo Nordisk is rebranding its diabetes pill under the Ozempic name

Novo Nordisk is preparing to launch an oral (pill) version of Ozempic, its semaglutide diabetes drug, in the United States. This expands the company's options beyond the injectable form already available to American patients.

• •Novo Nordisk is preparing a US launch of an oral version of Ozempic
• •Oral formulation uses semaglutide, same molecule as injectable Ozempic
• •Expands Novo's US options beyond the existing injectable form

• •Lilly and Novo Nordisk shares dipped on the news
• •A proposed Medicare coverage pilot for GLP-1s has been thrown off balance

• •Headline frames FDA GLP-1 compounding ruling as potentially favoring Hims & Hers

Counterfeit tirzepatide (a weight-loss and diabetes drug) was discovered in India's Haryana region, prompting Eli Lilly to warn people to buy the drug only with a prescription from a doctor. The company is trying to stop fake versions from reaching patients.

• •Counterfeit tirzepatide discovered in Haryana, India
• •Eli Lilly issued a safety warning urging prescription-only purchases
• •Company taking action to prevent fake versions reaching patients

• •Novo Nordisk faces first G7 generic semaglutide test
• •AI shift cited as additional competitive pressure on Novo

Eli Lilly rejected a recommendation from Australia's PBS (the agency that decides which medicines get government funding) about how to price and distribute Mounjaro in the country. The decision means negotiations over coverage and affordability for this tirzepatide weight-loss drug are still ongoing.

• •Eli Lilly rejected a PBS recommendation regarding Mounjaro in Australia.
• •PBS subsidy negotiations for tirzepatide remain unresolved.